Earn CME: https://www.naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Michael A. Choti argues in favor of utilizing adjuvant FOLFIRINOX for the treatment of pancreatic cancer. © 2019 Imedex, an HMP Company
Pancreatic Cancer Debate: Optimal Therapy – Adjuvant FOLFIRINOX
